Group | PFS | OS | ORR | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
No.of studies | HR (95% CI) | P | I2 (%) | No.of studies | RR (95% CI) | P | I2 (%) | No.of studies | RR (95% CI) | P | I2 (%) | |
Total | 24 | 1.04 (0.97–1.10) | 0.26 | 38 | 21 | 1.04 (0.89–1.21) | 0.61 | 58 | 13 | 1.08 (1.00–1.18) | 0.06 | 20 |
Nation | ||||||||||||
Keroa | 8 | 0.89 (0.78–1.02) | 0.09 | 18 | 8 | 1.03 (0.85–1.23) | 0.79 | 0 | 5 | 1.18 (0.94–1.49) | 0.16 | 0 |
China | 6 | 1.05 (0.88–1.25) | 0.63 | 20 | 5 | 0.92 (0.62–1.36) | 0.67 | 67 | 2 | 0.87 (0.70–1.08) | 0.21 | 0 |
Japan | 6 | 1.15 (0.98–1.36) | 0.09 | 20 | 4 | 1.04 (0.84–1.27) | 0.74 | 0 | 3 | 1.18 (0.98–1.41) | 0.08 | 0 |
Taiwan | 4 | 1.09 (0.77–1.54) | 0.62 | 74 | 4 | 1.12 (0.75–1.67) | 0.59 | 90 | 3 | 1.07 (0.86–1.35) | 0.54 | 71 |
Tumor stage | ||||||||||||
IIIb-IV | 22 | 1.04 (0.98–1.10) | 0.23 | 40 | 18 | 1.08 (0.92–1.26) | 0.34 | 53 | 12 | 1.09 (1.00–1.18) | 0.05 | 24 |
I-IV | 2 | 0.77 (0.39–1.51) | 0.45 | 25 | 3 | 0.54 (0.18–1.63) | 0.27 | 80 | 1 | 0.46 (0.05–4.01) | 0.48 | NA |
History | ||||||||||||
Non-squamous | 13 | 1.04 (0.96–1.14) | 0.88 | 51 | 11 | 1.06 (0.86–1.31) | 0.58 | 68 | 9 | 1.08 (0.99–1.17) | 0.09 | 42 |
Squamous included | 10 | 1.02 (0.94–1.12) | 0.6 | 11 | 9 | 0.98(0.86–1.13) | 0.81 | 48 | 4 | 1.19 (0.81–1.77) | 0.38 | 0 |
Unclear | 1 | 3.05 (0.84–11.09) | 0.09 | NA | 1 | 1.34 (0.49–3.67) | 0.57 | NA | ||||
Treatment line | ||||||||||||
First line included | 14 | 1.09 (0.98–1.20) | 0.11 | 46 | 11 | 0.97 (0.72–1.30) | 0.82 | 77 | 7 | 1.06 (0.90–1.25) | 0.52 | 52 |
Second line or later | 8 | 1.01 (0.93–1.08) | 0.89 | 22 | 8 | 1.02 (0.91–1.14) | 0.78 | 0 | 6 | 1.15 (0.98–1.35) | 0.08 | 0 |
First line only | 3 | 0.89 (0.32–2.49) | 0.82 | 66 | 2 | 0.24 (0.04–1.43) | 0.12 | 75 | ||||
Second line only | 3 | 0.93 (0.76–1.14) | 0.5 | 0 | 2 | 1.25 (0.90–1.73) | 0.19 | 0 | 2 | 1.18 (0.76–1.82) | 0.47 | 0 |
Third line only | 1 | 0.88 (0.43–1.79) | 0.72 | NA | 2 | 0.96 (0.81–1.14) | 0.47 | 0 | 1 | 0.46 (0.05–4.01) | 0.48 | NA |
Unclear | 2 | 1.48 (0.72–3.08) | 0.29 | 43 | 2 | 1.22 (0.62–2.39) | 0.56 | 0 | ||||
EGFR mutation | ||||||||||||
Partial mutation | 11 | 1.02 (0.91–1.15) | 0.68 | 21 | 11 | 1.15 (0.91–1.45) | 0.24 | 68 | 9 | 1.10 (1.00–1.21) | 0.05 | 21 |
All mutation | 9 | 1.11 (0.90–1.36) | 0.33 | 50 | 7 | 0.82 (0.54–1.25) | 0.36 | 59 | 2 | 0.88 (0.71–1.09) | 0.24 | 0 |
Unclear | 4 | 0.98 (0.76–1.26) | 0.88 | 57 | 3 | 0.97 (0.84–1.13) | 0.67 | 0 | 2 | 1.22 (0.92–1.62) | 0.18 | 2 |
Study design | ||||||||||||
Retrospective study | 21 | 1.02 (0.95–1.09) | 0.37 | 40 | 18 | 1.01 (0.84–1.21) | 0.92 | 63 | 10 | 1.10 (1.00–1.22) | 0.06 | 19 |
RCT | 3 | 1.11 (0.96–1.27) | 0.15 | 32 | 3 | 1.11 (0.93–1.32) | 0.25 | 0 | 3 | 1.04 (0.90–1.20) | 0.62 | 36 |